Positive CHMP Opinion For Xtandi™ (Enzalutamide) In Advanced Prostate Cancer
Enzalutamide recommended for approval in the European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy 1 Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Pharmaceuticals | Prostate Cancer | Taxotere